Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

439753

registered interest
date	22/12/2015
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Motor Vehicles: Exhaust Emissions
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government why their representatives at the Technical Committee on Motor Vehicles voted on 28 October to weaken and delay the introduction of real driving emissions tests for air pollution emissions by diesel light duty vehicles.
tabling member printed	Baroness Randerson
uin	HL4806
answer	answer is ministerial correction date of answer 07/01/2016 answer text <p>Government officials voted to secure the best possible outcome on the 28<sup>th</sup> October. This meant ensuring that real driving emissions tests will be introduced as early as possible and so make a significant contribution towards lowering emissions of nitrogen oxides from light duty diesel vehicles.</p> answering member printed Lord Ahmad of Wimbledon question first answered 07/01/2016 12:41:46 answering member 4210 label Biography information for Lord Ahmad of Wimbledon
tabling member	4230 label Biography information for Baroness Randerson

439754

registered interest
date	22/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Negligence
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what was the total cost of clinical negligence in hospitals in each of the last 10 years.
tabling member printed	Lord Storey
uin	HL4807
answer	answer is ministerial correction date of answer 06/01/2016 answer text <p>The information requested is in the following table, provided by the NHS Litigation Authority (NHSLA).</p><br /><p>All payments made by the NHSLA in respect of clinical negligence claims against the NHS in hospitals in each of the last ten years.</p><br /><table><tbody><tr><td><p>Year of Payment</p></td><td><p>Total Paid £'000</p></td></tr><tr><td><p>2005/06</p></td><td><p>560,308</p></td></tr><tr><td><p>2006/07</p></td><td><p>579,390</p></td></tr><tr><td><p>2007/08</p></td><td><p>633,325</p></td></tr><tr><td><p>2008/09</p></td><td><p>769,226</p></td></tr><tr><td><p>2009/10</p></td><td><p>786,991</p></td></tr><tr><td><p>2010/11</p></td><td><p>863,398</p></td></tr><tr><td><p>2011/12</p></td><td><p>1,277,372</p></td></tr><tr><td><p>2012/13</p></td><td><p>1,258,880</p></td></tr><tr><td><p>2013/14</p></td><td><p>1,192,540</p></td></tr><tr><td><p>2014/15</p></td><td><p>1,169,587</p></td></tr></tbody></table><p><em></em></p><p><em></em></p><p><em>Notes:</em></p><p><em>1. December 2015</em></p><p><em>2. These figures cover England only.</em></p><p><em>3. They represent payments under the various NHS LA Clinical negligence schemes:</em></p><p>‒ <em>Clinical Negligence Scheme for Trusts;</em></p><p>‒ <em>Existing Liabilities Scheme; and</em><em></em></p><p>‒ <em>Ex-Regional Health Authorities Scheme.</em></p><p><em>4. It excludes private insurance cases.</em></p> answering member printed Lord Prior of Brampton question first answered 06/01/2016 14:56:26 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4238 label Biography information for Lord Storey

439755

registered interest
date	22/12/2015
answering body	HM Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	CaTreasury
hansard heading	National Savings Bonds: Pensioners
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether they will clarify whether they intend to reissue the 65+ Guarantee of Growth Bonds as and when they mature.
tabling member printed	Lord Trefgarne
uin	HL4808
answer	answer is ministerial correction date of answer 08/01/2016 answer text <p>65+ GGB “Pensioner” Bonds were a special issue aimed at helping pensioners who rely on their savings in retirement. There are currently no plans for a further issue.</p> answering member printed Lord O'Neill of Gatley question first answered 08/01/2016 14:02:35 answering member 4536 label Biography information for Lord O'Neill of Gatley
tabling member	1813 label Biography information for Lord Trefgarne

439756

registered interest
date	22/12/2015
answering body	Ministry of Justice
answering dept id	54
answering dept short name	Justice
answering dept sort name	Justice
hansard heading	Prisoners: Females
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by Lord Faulks on 17 December (HL4250), whether they now have any additional information about the number of women responsible for one or more young children who are currently serving prison sentences in England and Wales.
tabling member printed	Lord Trefgarne
uin	HL4809
answer	answer is ministerial correction date of answer 08/01/2016 answer text <p>Whilst the specific information requested is not held, the Ministry of Justice recently published statistics on child dependents of female offenders, which can be found at gov.uk on the <em>Statistics at MOJ</em> pages under the topic <em>Ad-hoc justice statistics</em>. A copy of the report is attached here.</p> answering member printed Lord Faulks question first answered 08/01/2016 14:04:25 answering member 4183 label Biography information for Lord Faulks attachment 1 file name female-offenders-child-dependents-statistics.pdf title Female offenders, dependent child stats
tabling member	1813 label Biography information for Lord Trefgarne

439757

registered interest
date	22/12/2015
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Road Traffic Control
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by Lord Ahmad of Wimbledon on 14 December (HL4061), what checks are in place to ensure that Regulation 6 of the Local Authorities' Traffic Orders (Procedure) (England and Wales) Regulations 1996 is complied with; who is entitled to complain if that Regulation is not complied with, and to whom; and what penalties are incurred by local authorities or London boroughs for failing to comply with that regulation.
tabling member printed	Baroness Wolf of Dulwich
uin	HL4810
answer	answer is ministerial correction date of answer 07/01/2016 answer text <p>There are no checks in place to ensure that local authorities comply with the Local Authorities’ Traffic Orders (Procedure) (England and Wales) Regulations 1996, including the duty concerning consultation. Anyone can complain if they consider that the authority has failed to comply with their duty. Complaints should initially be raised with the authority concerned, and if they are not satisfactorily addressed, they can be raised with the Local Government Ombudsman. Alternatively, failure to comply with the consultation requirements in regulation 6 would be grounds for bringing a legal challenge against an order under paragraph 35 of Schedule 9 to the Road Traffic Regulation Act 1984.</p> answering member printed Lord Ahmad of Wimbledon question first answered 07/01/2016 12:39:48 answering member 4210 label Biography information for Lord Ahmad of Wimbledon
tabling member	4347 label Biography information for Baroness Wolf of Dulwich

439758

registered interest
date	22/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Biomedicines
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what work has been undertaken by NHS England to ensure that prescribers and commissioners have the right information to introduce biosimilar medicines in a safe and sustainable way.
tabling member printed	Baroness Brinton
uin	HL4811
answer	answer is ministerial correction date of answer 06/01/2016 answer text <p>NHS England is undertaking a programme of work to engage, inform and support commissioners, clinicians, pharmacists, patients and others in their consideration of the optimal use of biosimilar medicines. In September 2015 they published a <em>What is a Biosimilar Medicine?</em> guide, which provides an update for clinical and non-clinical stakeholders about the developing role of biosimilar medicines in the NHS in England and to support the safe, effective and consistent use of all biological medicines, including biosimilar medicines, to the benefit of patients. A copy is attached and is also available at:</p><br /><p><a href="https://www.england.nhs.uk/wp-content/uploads/2015/09/biosimilar-guide.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2015/09/biosimilar-guide.pdf</a></p><br /><p>NHS England has also convened a National Biosimilar Medicines Group, chaired by the Chief Pharmaceutical Officer, whose role includes improving education and understanding of both the theory and practical considerations related to biosimilar medicines.</p><br /><p>Guidance to prescribers requires them to explain to patients the likely benefits, risks and burdens, including serious and common side effects of treatments they are proposing. The <em>What is a Biosimilar Medicine?</em> guide makes it clear that patients’ needs preferences and values are an essential part of evidence based medicine. Local collaborations involving both patients and clinicians have been successful in introducing biosimilars.</p> answering member printed Lord Prior of Brampton grouped question UIN HL4812 question first answered 06/01/2016 15:04:22 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name HL4811 HL4812 - library document.pdf title What is a biosimilar medicine?
tabling member	4241 label Biography information for Baroness Brinton

439759

registered interest
date	22/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Biomedicines
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what provisions have been put in place by NHS England to ensure that patients who are being prescribed biosimilar medicines are informed about the medicines and have given their consent.
tabling member printed	Baroness Brinton
uin	HL4812
answer	answer is ministerial correction date of answer 06/01/2016 answer text <p>NHS England is undertaking a programme of work to engage, inform and support commissioners, clinicians, pharmacists, patients and others in their consideration of the optimal use of biosimilar medicines. In September 2015 they published a <em>What is a Biosimilar Medicine?</em> guide, which provides an update for clinical and non-clinical stakeholders about the developing role of biosimilar medicines in the NHS in England and to support the safe, effective and consistent use of all biological medicines, including biosimilar medicines, to the benefit of patients. A copy is attached and is also available at:</p><br /><p><a href="https://www.england.nhs.uk/wp-content/uploads/2015/09/biosimilar-guide.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2015/09/biosimilar-guide.pdf</a></p><br /><p>NHS England has also convened a National Biosimilar Medicines Group, chaired by the Chief Pharmaceutical Officer, whose role includes improving education and understanding of both the theory and practical considerations related to biosimilar medicines.</p><br /><p>Guidance to prescribers requires them to explain to patients the likely benefits, risks and burdens, including serious and common side effects of treatments they are proposing. The <em>What is a Biosimilar Medicine?</em> guide makes it clear that patients’ needs preferences and values are an essential part of evidence based medicine. Local collaborations involving both patients and clinicians have been successful in introducing biosimilars.</p> answering member printed Lord Prior of Brampton grouped question UIN HL4811 question first answered 06/01/2016 15:04:28 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name HL4811 HL4812 - library document.pdf title What is a biosimilar medicine?
tabling member	4241 label Biography information for Baroness Brinton

439760

registered interest
date	22/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Biosimilar Medicines: Prescriptions
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government which organisation has responsibility for ensuring implementation and compliance with the Medicines and Healthcare products Regulatory Agency guidance, which states that biologic medicines should be prescribed by brand name and tracked by batch number.
tabling member printed	Baroness Brinton
uin	HL4813
answer	answer is ministerial correction date of answer 05/01/2016 answer text <p>In 2008, the Medicines and Healthcare products Regulatory Agency (MHRA) issued best practice guidance on the prescribing of biological products. This advised:</p><br /><p>“All biosimilar products are prescription only medicines (POM). When prescribing biological products, it is good practice to use the brand name. This will ensure that automatic substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist. Products (biosimilar and reference) that have the same international non-proprietary name (INN) are not to be presumed identical for the reasons given above.”</p><br /><p>The MHRA does not have responsibility for monitoring the compliance of healthcare professionals with its prescribing guidance. The responsibility for prescribing rests with the practitioner who has clinical responsibility for their patient's care and we would expect practitioners to take any relevant guidance into account when making their prescribing decisions. Practitioner professional bodies also have a role in setting out best practice to their members.</p> answering member printed Lord Prior of Brampton question first answered 05/01/2016 10:12:27 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4241 label Biography information for Baroness Brinton

439761

registered interest
date	22/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Safety
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government which organisation has responsibility for ensuring compliance with EU legislation on pharmacovigilance.
tabling member printed	Baroness Brinton
uin	HL4814
answer	answer is ministerial correction date of answer 06/01/2016 answer text <p>The Medicines and Healthcare products Regulatory Agency has the responsibility for ensuring compliance with European Union legislation on pharmacovigilance.</p> answering member printed Lord Prior of Brampton question first answered 06/01/2016 14:50:55 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4241 label Biography information for Baroness Brinton

439762

registered interest
date	22/12/2015
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Motor Vehicles: Exhaust Emissions
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, in making their decision about how to vote on the implementation of real driving emissions tests at the 28 October meeting of the Technical Committee on Motor Vehicles, whether they took into account (1) estimates from DEFRA and Public Health England that pollution from mono-nitrogen oxides is responsible for 23,500 premature deaths in the UK per annum, (2) the 2010 estimates from the WHO suggesting that air-pollution related deaths cost the UK $83,069 per annum, (3) the failure of London, Leeds, and Birmingham to maintain nitrogen dioxide levels within legal limits over the past five years, and (4) the Supreme Court’s ruling in <i>R (on the application of ClientEarth) v Secretary of State for the Environment, Food and Rural Affairs </i>[2015] UKSC 28 on 29 April that they should take immediate action to tackle air pollution.
tabling member printed	Baroness Falkner of Margravine
uin	HL4815
answer	answer is ministerial correction date of answer 07/01/2016 answer text <p>The Government is committed to taking action on vehicle emissions testing that restores consumer confidence and delivers our wider air quality and climate objectives. We strongly support the current Real Driving Emissions agreement, which is expected to significantly reduce average real world NOx emissions from new diesel cars from 2017. It makes type approval requirements for diesel vehicles significantly more stringent by requiring manufacturers to ensure real-world emissions are maintained below 2.1 times the laboratory-testing limit in 2017 and at or below the laboratory-testing limit by 2020 (with a margin for measurement uncertainty). Issues relating to vehicle emissions are considered in the context of the UK Government’s plans for air quality. More detail is set out in the air quality plans published by the Department for Environment, Food and Rural Affairs on the 17<sup>th</sup> December.</p> answering member printed Lord Ahmad of Wimbledon question first answered 07/01/2016 12:42:17 answering member 4210 label Biography information for Lord Ahmad of Wimbledon
tabling member	3670 label Biography information for Baroness Falkner of Margravine